-ESMFold2 is validated in the lab across five therapeutic targets. Inversion of ESMFold2 enables generation of de novo minibinders and antibody-derived scFvs with high hit rates, nanomolar affinities, target specificity, and functional activity. We've released the full protocol from target sequence to ranked binder design in this [notebook](https://github.com/Biohub/esm/blob/main/cookbook/tutorials/esmfold2_esmc_binder_design.ipynb). For additional details, please refer to the [preprint](https://biohub.ai/papers/esm_protein.pdf).
0 commit comments